Nurix Therapeutics/$NRIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Ticker
$NRIX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
286
ISIN
US67080M1036
Website
NRIX Metrics
BasicAdvanced
$903M
-
-$2.81
2.24
-
Price and volume
Market cap
$903M
Beta
2.24
52-week high
$27.37
52-week low
$8.18
Average daily volume
787K
Financial strength
Current ratio
6.264
Quick ratio
6.132
Long term debt to equity
4.155
Total debt to equity
5.536
Profitability
EBITDA (TTM)
-222.349
Gross margin (TTM)
-327.69%
Net profit margin (TTM)
-369.40%
Operating margin (TTM)
-408.87%
Effective tax rate (TTM)
-0.09%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
-31.08%
Return on equity (TTM)
-64.16%
Valuation
Price to revenue (TTM)
15.59
Price to book
1.88
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-4.363
Free cash flow yield (TTM)
-22.92%
Free cash flow per share (TTM)
-271.38%
Growth
Revenue change (TTM)
-30.25%
Earnings per share change (TTM)
5.75%
3-year revenue growth (CAGR)
17.97%
3-year earnings per share growth (CAGR)
-2.77%
What the Analysts think about NRIX
Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.
Bulls say / Bears say
Nurix Therapeutics secured FDA Orphan Drug Status for its BTK degrader, enhancing its potential in treating rare diseases. (stocktitan.net)
The company successfully raised $175 million through an upsized public offering, bolstering its financial position for future developments. (biospace.com)
Analysts maintain a 'Moderate Buy' rating with an average price target of $30.88, indicating confidence in the company's growth prospects. (americanbankingnews.com)
Nurix reported a net loss of $56.4 million for Q1 2025, reflecting ongoing financial challenges. (stocktitan.net)
Insider selling activity, including CFO Hans van Houte's sale of $84,387 in stock, may raise concerns about internal confidence. (investing.com)
Wells Fargo reduced its price target for Nurix to $25.00, suggesting tempered expectations for the stock's performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
NRIX Financial Performance
Revenues and expenses
NRIX Earnings Performance
Company profitability
NRIX News
AllArticlesVideos
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
GlobeNewsWire·2 weeks ago
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nurix Therapeutics stock?
Nurix Therapeutics (NRIX) has a market cap of $903M as of June 27, 2025.
What is the P/E ratio for Nurix Therapeutics stock?
The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of June 27, 2025.
Does Nurix Therapeutics stock pay dividends?
No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Nurix Therapeutics dividend payment date?
Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nurix Therapeutics?
Nurix Therapeutics (NRIX) has a beta rating of 2.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.